CAR T-cell therapy Archives - Medical Design Sourcing

10x Genomics’ Chromium platform sheds light on CAR T-cell therapy persistence

[Eliana/CAR T-cell therapy]

Therapy persistence is a vital factor in determining the success of CAR-Ts for blood cancers like leukemia. While CAR-Ts hold great promise for blood cancers such as leukemia, in some cases, the durability of the treatment falls short, leading to a potential relapse. A positive study from researchers at University College London, Great Ormond Street Hospital and the Wellcome Sanger Institute, published in Nature Medicine sheds light on the challenge and ways to address it.

Examining CAR T-cell therapy persistence in the CARPALL trial

Investigating patients from the phase 1 CARPALL trial, the study considered patients who underwent CAR T-cell therapy (AUTO1) to treat B-cell acute lymphoblastic leukemia (B-ALL), a rare and aggressive pediatric blood cancer. Focusing on an advanced therapy investigational medicinal product (ATIMP) designed to combat CD19+ or CD22+ acute lymphoblastic le…

How Cellares aims to transform cell therapy manufacturing

The startup Cellares has a mission to enable industrial-scale cell therapy manufacturing with its Cell Shuttle, which it dubs a “factory in a box.”

The germ for the idea traces back to market research that South San Francisco, California-based Cellares co-founder and CEO Fabian Gerlinghaus focused on in a prior role. While attending industry conferences, Gerlinghaus stumbled upon traditional cell therapy manufacturing challenges and the opportunity to accelerate the process. “At these conferences, people were shouting from the rooftops, ‘We need cell therapy manufacturing technologies that are fully automated, fully closed and scalable to produce these life-saving therapeutics at a large scale for all the patients who need them,'” Gerlinghaus recounted.

Fabian Gerlinghaus

Cellares was born in April 2019 and has raised $100 million to date.

One of the chief objectiv…

Novartis is upbeat about the future of CAR-Ts and TCRs

The life sciences industry has just scratched the surface in terms of chimeric antigen receptor (CAR) T-cell therapy’s potential, according to a session at the Novartis Breakthrough Science media event held on November 10.

CAR-T therapy, which has emerged as one of the most promising new treatments for multiple myeloma, certain lymphomas and B-cell acute lymphoblastic leukemia, has found growing use in recent years. The treatment, however, is often expensive.

Manufacturing of CAR-Ts continues to improve, however. And in recent years, researchers have made progress in enhancing the fitness of CAR-T cells so that they have more potential for proliferation and “hopefully, overall, better benefit and higher response rates,” said Jennifer Brogdon, executive director, head of cell therapy research, department of exploratory immuno-oncology at the Novartis Institutes for BioMedical Research.

Manufacturing breakthroughs have enabled the therapy to be used …